Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14962804 | 0.87 | HPGD (0.81) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL2091479 | 0.82 | HPGD (0.70) | HPGDSMN1; SMN2RAB9AALDH1A1MAPT | |
| SCHEMBL853933 | 0.82 | HPGD (0.70) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL13471890 | 0.81 | SMN1; SMN2 (0.68) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL178525 | 0.81 | HPGD (0.68) | HPGDSMN1; SMN2ALDH1A1MAPTALOX12 | |
| SCHEMBL1976948 | 0.80 | HPGD (0.71) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL104611 | 0.80 | SMN1; SMN2 (0.67) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL764569 | 0.80 | HPGD (0.71) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL22854085 | 0.80 | HPGD (0.71) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL12545584 | 0.80 | SMN1; SMN2 (0.67) | HPGDSMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020261294-A1 | NOVEL APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS | MANKIND PHARMA LTD. (IN) | 2020-12-30 | — | — | WO | disclosed |
| US-9896432-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2018-01-18 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253158-B2 | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | HPGD 4110/4885SMN1; SMN2 4581/4885RAB9A 3030/4885 |
| US-20180016252-A1 | SOMATOSTATIN MODULATORS AND USES THEREOF | SSTR5, SSTR2, SSTR4 | HPGD 1517/4885SMN1; SMN2 1197/4885RAB9A 2145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.